224 related articles for article (PubMed ID: 29318653)
1. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
Desai K; Catalano T; Rai G; Misra P; Shah N
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
[TBL] [Abstract][Full Text] [Related]
4. A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.
Brekkan A; Lopez-Lazaro L; Yngman G; Plan EL; Acharya C; Hooker AC; Kankanwadi S; Karlsson MO
AAPS J; 2018 Aug; 20(5):91. PubMed ID: 30112626
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients.
Li L; Ma L; Schrieber SJ; Rahman NA; Deisseroth A; Farrell AT; Wang Y; Sinha V; Marathe A
Clin Pharmacol Ther; 2018 Oct; 104(4):742-748. PubMed ID: 29392707
[TBL] [Abstract][Full Text] [Related]
7. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.
Li Y; Klippel Z; Shih X; Wang H; Reiner M; Page JH
Cancer Chemother Pharmacol; 2016 Apr; 77(4):703-12. PubMed ID: 26886017
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
10. A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):671-683. PubMed ID: 33793091
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Scholz M; Engel C; Apt D; Sankar SL; Goldstein E; Loeffler M
Cell Prolif; 2009 Dec; 42(6):823-37. PubMed ID: 19780759
[TBL] [Abstract][Full Text] [Related]
13. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
Molineux G
Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
[TBL] [Abstract][Full Text] [Related]
14. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.
Roskos LK; Lum P; Lockbaum P; Schwab G; Yang BB
J Clin Pharmacol; 2006 Jul; 46(7):747-57. PubMed ID: 16809800
[TBL] [Abstract][Full Text] [Related]
16. LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
[TBL] [Abstract][Full Text] [Related]
18. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
Johnston E; Crawford J; Blackwell S; Bjurstrom T; Lockbaum P; Roskos L; Yang BB; Gardner S; Miller-Messana MA; Shoemaker D; Garst J; Schwab G
J Clin Oncol; 2000 Jul; 18(13):2522-8. PubMed ID: 10893282
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors.
Lee S; Hong KT; Moon SJ; Choi JY; Hong CR; Shin HY; Cho JY; Jang IJ; Yu KS; Oh J; Kang HJ
Clin Pharmacol Ther; 2022 Jan; 111(1):293-301. PubMed ID: 34605552
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
